usana health sciences - USNA
USNA
Close Chg Chg %
20.34 0.16 0.79%
Pre-Market
20.50
+0.16 (0.79%)
Volume: 174.05K
Last Updated:
Jan 14, 2026, 3:59 PM EDT
Company Overview: usana health sciences - USNA
USNA Key Data
| Open $20.30 | Day Range 20.20 - 20.77 |
| 52 Week Range 18.50 - 38.32 | Market Cap $376.59M |
| Shares Outstanding 18.28M | Public Float 10.77M |
| Beta 0.64 | Rev. Per Employee N/A |
| P/E Ratio 23.14 | EPS $0.89 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 129.40K |
USNA Performance
| 1 Week | 3.17% | ||
| 1 Month | 0.24% | ||
| 3 Months | -1.96% | ||
| 1 Year | -39.80% | ||
| 5 Years | -74.18% |
USNA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About usana health sciences - USNA
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.
USNA At a Glance
USANA Health Sciences, Inc.
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
| Phone | 1-801-954-7100 | Revenue | 854.50M | |
| Industry | Pharmaceuticals: Other | Net Income | 42.03M | |
| Sector | Health Technology | Employees | 1,700 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
USNA Valuation
| P/E Current | 23.143 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 16.272 |
| Price to Sales Ratio | 0.80 |
| Price to Book Ratio | 1.279 |
| Price to Cash Flow Ratio | 11.21 |
| Enterprise Value to EBITDA | 6.725 |
| Enterprise Value to Sales | 0.697 |
| Total Debt to Enterprise Value | 0.066 |
USNA Efficiency
| Revenue/Employee | 502,648.824 |
| Income Per Employee | 24,723.529 |
| Receivables Turnover | 103.916 |
| Total Asset Turnover | 1.238 |
USNA Liquidity
| Current Ratio | 1.993 |
| Quick Ratio | 1.494 |
| Cash Ratio | 1.302 |
USNA Profitability
| Gross Margin | 79.432 |
| Operating Margin | 7.762 |
| Pretax Margin | 8.935 |
| Net Margin | 4.919 |
| Return on Assets | 6.087 |
| Return on Equity | 7.758 |
| Return on Total Capital | 6.719 |
| Return on Invested Capital | 7.65 |
USNA Capital Structure
| Total Debt to Total Equity | 6.686 |
| Total Debt to Total Capital | 6.267 |
| Total Debt to Total Assets | 5.24 |
| Long-Term Debt to Equity | 1.915 |
| Long-Term Debt to Total Capital | 1.629 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Usana Health Sciences - USNA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.19B | 998.60M | 921.01M | 854.50M | |
Sales Growth
| +4.57% | -15.83% | -7.77% | -7.22% | |
Cost of Goods Sold (COGS) incl D&A
| 230.93M | 207.28M | 189.40M | 175.75M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 22.19M | 21.41M | 20.39M | 22.23M | |
Depreciation
| 21.01M | 19.69M | 18.56M | 20.71M | |
Amortization of Intangibles
| 1.18M | 1.72M | 1.83M | 1.52M | |
COGS Growth
| +3.62% | -10.24% | -8.63% | -7.20% | |
Gross Income
| 955.53M | 791.32M | 731.62M | 678.75M | |
Gross Income Growth
| +4.80% | -17.19% | -7.54% | -7.23% | |
Gross Profit Margin
| +80.54% | +79.24% | +79.44% | +79.43% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 785.34M | 683.70M | 638.54M | 612.43M | |
Research & Development
| 11.11M | 11.56M | 11.45M | 11.57M | |
Other SG&A
| 774.23M | 672.14M | 627.10M | 600.86M | |
SGA Growth
| +6.81% | -12.94% | -6.61% | -4.09% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| 170.19M | 107.61M | 93.07M | 66.32M | |
Non Operating Income/Expense
| 507.00K | 1.20M | 9.64M | 10.31M | |
Non-Operating Interest Income
| 2.52M | 3.79M | 9.64M | 11.32M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 57.00K | 192.00K | 262.00K | 281.00K | |
Interest Expense Growth
| -88.76% | +236.84% | +36.46% | +7.25% | |
Gross Interest Expense
| 57.00K | 192.00K | 262.00K | 281.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 170.64M | 108.62M | 102.45M | 76.35M | |
Pretax Income Growth
| -4.11% | -36.35% | -5.68% | -25.48% | |
Pretax Margin
| +14.38% | +10.88% | +11.12% | +8.94% | |
Income Tax
| 54.14M | 39.27M | 38.66M | 34.29M | |
Income Tax - Current - Domestic
| 303.00K | 339.00K | 427.00K | 330.00K | |
Income Tax - Current - Foreign
| 56.67M | 45.87M | 40.91M | 40.70M | |
Income Tax - Deferred - Domestic
| (4.13M) | (9.51M) | (4.09M) | (6.90M) | |
Income Tax - Deferred - Foreign
| 1.29M | 2.57M | 1.42M | 165.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 116.50M | 69.35M | 63.79M | 42.06M | |
Minority Interest Expense
| - | - | - | 30.00K | - |
Net Income
| 116.50M | 69.35M | 63.79M | 42.03M | |
Net Income Growth
| -6.54% | -40.47% | -8.02% | -34.11% | |
Net Margin Growth
| +9.82% | +6.94% | +6.93% | +4.92% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 116.50M | 69.35M | 63.79M | 42.03M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 116.50M | 69.35M | 63.79M | 42.03M | |
EPS (Basic)
| 5.783 | 3.6018 | 3.3137 | 2.2002 | |
EPS (Basic) Growth
| -1.86% | -37.72% | -8.00% | -33.60% | |
Basic Shares Outstanding
| 20.15M | 19.25M | 19.25M | 19.10M | |
EPS (Diluted)
| 5.727 | 3.5914 | 3.2974 | 2.1934 | |
EPS (Diluted) Growth
| -2.35% | -37.29% | -8.19% | -33.48% | |
Diluted Shares Outstanding
| 20.34M | 19.31M | 19.34M | 19.16M | |
EBITDA
| 192.38M | 129.02M | 113.47M | 88.55M | |
EBITDA Growth
| -3.32% | -32.93% | -12.06% | -21.96% | |
EBITDA Margin
| +16.21% | +12.92% | +12.32% | +10.36% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 39.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | 0.40 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 1.90 | |
| Last Quarter’s Earnings | 0.40 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.73 | Next Fiscal Year Estimate | 2.76 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | 1 |
| Mean Estimate | 0.40 | 0.44 | 1.90 | 2.76 |
| High Estimates | 0.40 | 0.44 | 1.90 | 2.76 |
| Low Estimate | 0.40 | 0.44 | 1.90 | 2.76 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 0 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Usana Health Sciences - USNA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Usana Health Sciences - USNA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 5, 2025 | Gilbert A. Fuller Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.48 per share | 0.00 |
| Nov 3, 2025 | John T. Fleming Director | 4,565 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $19.79 per share | 90,341.35 |
| Oct 28, 2025 | Frederic J. Winssinger Director | 7,986 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | J. Scott Nixon Director | 7,698 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | J. Scott Nixon Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Peggie Pelosi Director | 5,192 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Xia Ding Director | 6,394 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | John T. Fleming Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Peggie Pelosi Director | 4,586 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $20.63 per share | 94,609.18 |
| Oct 28, 2025 | Frederic J. Winssinger Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Timothy E. Wood Director | 9,292 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Xia Ding Director | 5,918 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $20.63 per share | 122,088.34 |
| Oct 28, 2025 | Xia Ding Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Gilbert A. Fuller Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Peggie Pelosi Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Timothy E. Wood Director | 2,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Timothy E. Wood Director | 9,027 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $20.63 per share | 186,227.01 |
| Jul 29, 2025 | Kathryn Armstrong CHIEF SCIENTIFIC OFFICER | 20,256 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 29, 2025 | Jim H. Brown CEO & PRESIDENT | 17,906 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 29, 2025 | Jim H. Brown CEO & PRESIDENT | 16,934 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.09 per share | 543,412.06 |